David Bianculli

And that's how she said they viewed these price increases.

Yeah. Might be a bad story here or there or a bad tweet. But, you know, why wouldn't we take the increases is what she quoted him as saying.

Yeah. Might be a bad story here or there or a bad tweet. But, you know, why wouldn't we take the increases is what she quoted him as saying.

Yeah. Might be a bad story here or there or a bad tweet. But, you know, why wouldn't we take the increases is what she quoted him as saying.

Well, I think the big reason is that here in the United States, we do not have a single payer of health care. We're one of the few countries where the government is not the provider or the sole provider of health care. And that makes it hard to negotiate. We have a very fractionalized system in terms of the number of payers.

Well, I think the big reason is that here in the United States, we do not have a single payer of health care. We're one of the few countries where the government is not the provider or the sole provider of health care. And that makes it hard to negotiate. We have a very fractionalized system in terms of the number of payers.

Well, I think the big reason is that here in the United States, we do not have a single payer of health care. We're one of the few countries where the government is not the provider or the sole provider of health care. And that makes it hard to negotiate. We have a very fractionalized system in terms of the number of payers.

You know, there's hundreds and hundreds of private payers, even among the government itself. There's Medicare, Medicaid, the Veterans Administration, Department of Defense, who are all big payers. So it's very hard to negotiate a price when everybody's doing their own negotiating.

You know, there's hundreds and hundreds of private payers, even among the government itself. There's Medicare, Medicaid, the Veterans Administration, Department of Defense, who are all big payers. So it's very hard to negotiate a price when everybody's doing their own negotiating.

You know, there's hundreds and hundreds of private payers, even among the government itself. There's Medicare, Medicaid, the Veterans Administration, Department of Defense, who are all big payers. So it's very hard to negotiate a price when everybody's doing their own negotiating.

Well, you know, I think, first of all, the administration should be given some credit for bringing attention to this issue and pledging to do something about it. I think the executive order didn't have a lot of specific mechanisms for how this is going to be accomplished. A lot of it will be down the road.

Well, you know, I think, first of all, the administration should be given some credit for bringing attention to this issue and pledging to do something about it. I think the executive order didn't have a lot of specific mechanisms for how this is going to be accomplished. A lot of it will be down the road.

Well, you know, I think, first of all, the administration should be given some credit for bringing attention to this issue and pledging to do something about it. I think the executive order didn't have a lot of specific mechanisms for how this is going to be accomplished. A lot of it will be down the road.

They talk about getting together with the drug companies and discussing prices of certain drugs. And if that doesn't work, they could turn to rulemaking. which would probably be Medicare and Medicaid programs instituting rules on what prices they will pay for drugs. But, you know, a lot of it is the devil's in the details here. And I think we'll have to see.

They talk about getting together with the drug companies and discussing prices of certain drugs. And if that doesn't work, they could turn to rulemaking. which would probably be Medicare and Medicaid programs instituting rules on what prices they will pay for drugs. But, you know, a lot of it is the devil's in the details here. And I think we'll have to see.

They talk about getting together with the drug companies and discussing prices of certain drugs. And if that doesn't work, they could turn to rulemaking. which would probably be Medicare and Medicaid programs instituting rules on what prices they will pay for drugs. But, you know, a lot of it is the devil's in the details here. And I think we'll have to see.

It's a complicated thing to get these prices down. You know, it doesn't even address the issue of what drug prices are launched at. You know, cancer drugs in particular are being launched at prices that are so expensive that, you know, you have nowhere to go when you start negotiating a decreased price because they started so high. So we'll have to see.

It's a complicated thing to get these prices down. You know, it doesn't even address the issue of what drug prices are launched at. You know, cancer drugs in particular are being launched at prices that are so expensive that, you know, you have nowhere to go when you start negotiating a decreased price because they started so high. So we'll have to see.

It's a complicated thing to get these prices down. You know, it doesn't even address the issue of what drug prices are launched at. You know, cancer drugs in particular are being launched at prices that are so expensive that, you know, you have nowhere to go when you start negotiating a decreased price because they started so high. So we'll have to see.

I think you can make the argument it is. And the reality with, you know, things like this executive order is that whatever comes from it in terms of real concrete actions is likely to be challenged in court. You know, the Trump administration ran into this problem the first time around.